Oxford Global is proud to present the inaugural Microbiome Discovery and Development Congress on 12 – 13 June 2017 at the Hotel Palace in Berlin, Germany. The event is co-located with the 5th Annual Discovery Chemistry and Drug Design Congress and the 18th Annual Drug Discovery Leaders Summit.
This congress will bring together key opinion leaders and senior industry experts in microbiome drug discovery to discuss the latest innovative discovery strategies and technologies, the commercialisation of the microbiome and the therapeutic potential. These topics have been compiled as a result of a comprehensive research process undertaken with an expert advisory board with members including Senior Directors and Professors from global pharmaceutical organisations, biotech companies and leading research institutions.
Over 250 microbiome and drug discovery attendees representing leading biotech companies, global pharmaceutical organisations and internationally renowned academic institutions.
Over 20 presentations, case studies and panel discussions focused on novel strategies in microbiome drug discovery and the therapeutic potential of the microbiome.
Including 3 Interactive Streams:
- Microbiome Discovery: Novel Strategies and Technologies
- Commercialising the Microbiome
- Therapeutic Potential of the Microbiome
The Microbiome industry is growing rapidly, with increased investment and a number of therapeutics in clinical development. As of yet, no drugs have been approved. Microbiome research therefore represents an exciting new area of drug discovery. Key challenges include the translation of academic research into clinically and commercially viable therapeutics, and the transfer of microbiome research from the food to the pharmaceutical industry. Our programme focusses on how best to approach these challenges.
On Day 1, we concentrate on the novel strategies and technologies utilised in microbiome research. It considers the different approaches, including small molecule microbiome discovery and live bacterial cultures, to pinpoint how our knowledge of the microbiome can be translated into microbiome drugs. Day 2 focusses on taking the next steps beyond this. The morning will be dedicated to a discussion of how new microbial drugs can be commercialised, in particular the regulatory and IP concerns of microbiome commercialisation. In the afternoon, the therapeutic potential of the microbiome is considered. Studies of the Gut Microbiome have dominated research and clinical studies, in particular when looking at C. difficile and inflammatory gut conditions. Interest is growing, however, in other areas of microbiome research, such as Dermatology and Women’s Health, and there will be talks dedicated to novel therapeutics in these areas.
- Johan van Hylckama Vlieg – Microbiome and Health Innovation, Chr-Hansen A/S
- Dirk Gevers – Janssen Human Microbiome Institute, Janssen
- Luc Sterkman – Caelus Health
- Jean de Gunzburg – Da Volterra
- Hervé Affagard – MaaT Pharma
- Xavier Duportet – Eligo Bioscience
- Greg Sieczkiewicz – MPM Capital
- Adam Baker – Microbiome and Human Health, Chr-Hansen A/S
- Dario Gutierrez – Immuno-Biology Lead, Merck Research Labs – Cambridge Exploratory Science Center, Merck
- Sonia Timberlake – Data Science, Finch Therapeutics
- Adrien Nivoliez – R&D and Business Development, biose®
- Francois-Pierre Martin – Nestle Institute of Health Sciences
- Sean Kennedy – Bio-Omics Pole, Institut Pasteur
- Tom van de Wiele – Host-Microbe Interaction Technology Group, Ghent University
Day 1: Microbiome Discovery: Novel Strategies and Technologies
- Translational Science of the Microbiome
- Metagenomics and Metatranscriptomics
- Formulating Computational and Mouse Models
- Single Cell Isotope Probing
- High-Throughput Screening
- Novel Genomic Technologies
- Next Generation Sequencing
- Data Management in Microbiome Discovery
- Biomarker Validation
- Small Molecule Microbiome Discovery
- Microbiome Identification
- FMT and related Microbiome Data
Part 1: Commercialising the Microbiome
- Regulatory Concerns
- IP Considerations in Europe vs. USA
- What would create action-forcing events for Global Biopharma companies?
- Global Research Collaboration
- Cross-disciplinary microbiome research: From Medical Nutrition to Pharma
- Promise of Microbiome Antibiotics and Peptides for Economic Sustainability
- Manufacturing the Microbiome
- Investing in the Microbiome
Part 2: Therapeutic Potential of the Microbiome
- Innovative Therapeutics in the Gut: Inflammatory, Gut-Brain Axis, Colon Cancer, Metabolic Disorders
- Growing Therapeutic Interest in: Dermatology, Respiratory, Women’s Health, Oral
- Personalised Therapeutics
- Relationship between antibiotics and microbiomes
Submit a poster
For attendees interested in submitting a poster, there are opportunities now available. Your poster presentation will be located in the exhibition room for two days alongside other posters from senior scientists working in industry and academia.
How to submit your poster
We will require:
- Poster title, Abstract (200 words or less)
- Principal author, Organisation
- Mailing address, Email, Telephone, Fax
- Additional authors
In order to secure your board space a fee of £250 will be required. The poster should be presented as A0 (841mm x 1189mm) portrait size. To take advantage of this opportunity you need to be registered as a paid delegate over the 2 days. We have limited spaces available, so please register soon!